Telomere dysfunction in human diseases: The long and short of it!

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 6, 2009, Pages 528-543

  Carroll, Kathryn A ^a   Ly, Hinh ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aplastic anemia; Dyskeratosis congenita; Idiopathic pulmonary fibrosis; Telomerase; Telomere

Indexed keywords

EID: 67650264860     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973;41:181-190.
2. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972;239:197-201.
3. Harley CB, Futcher AB and Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
4. Lindsey J, McGill NI, Lindsey LA, Green DK and Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45-48.
5. Harley CB, Vaziri H, Counter CM and Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol 1992;27:375-382.
6. Hayflick L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. Exp Cell Res 1965;37:614-636.
7. Autexier C and Lue NF. The Structure and Function of Telomerase Reverse Transcriptase. Ann Rev Biochem 2006;75: 493-517.
8. Chen JL and Greider CW. Telomerase RNA structure and function: implications for dyskeratosis congenita. Trends Biochem Sci 2004;29:183-192.
9. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-2110.
10. Dokal I and Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Reviews 2008;22:141-153.
11. Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A and Greider CW. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA 2005;102:15960-15964.
12. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA, 3rd, Lansdorp PM, Greider CW and Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-1326.
13. Basel-Vanagaite L, Dokal I, Tamary H, Avigdor A, Garty BZ, Volkov A and Vulliamy T. Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations. Haematologica 2008;93:943-944.
14. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL and Garcia CK. Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. Am J Respir Crit Care Med 2008;178:729-737.
15. u H-Y, Pumbo E, Manley P, Field JJ, Bayliss SJ, Wilson DB, Mason PJ and Bessler M. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood 2008;111:1128-1130.
16. Liang J, Yagasaki H, Kamachi Y, Hama A, Matsumoto K, Kato K, Kudo K and Kojima S. Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. Haematologica 2006;91:656-658.
17. Marrone A, Walne A, Tamary H, Masunari Y, Kirwan M, Beswick R, Vulliamy T and Dokal I. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007; 110:4198-4205.
18. Savage S, Stewart B, Weksler B, Baerlocher G, Lansdorp P, Chanock S and Alter B. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2006;37:134-136.
19. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW and Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:7552-7557.
20. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ and Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006;107:2680-2685.
21. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A and Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005;34: 257-263.
22. Xin ZT, Beauchamp AD, Calado RT, Bradford JW, Regal JA, Shenoy A, Liang Y, Lansdorp PM, Young NS and Ly H. Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood 2007;109:524-532.
23. Yamaguchi H, Calado, R. T., Ly, H., Kajigaya, S., Baerlocher, G. M., Chanock, S. J., Lansdorp, P. M., and Young, N. S. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New Engl J Med 2005;352:1413-1483.
24. Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, Lansdorp PM, Hogge D, Chanock SJ, Estey EH, Falcão RP and Young NS. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2009;106:1187-1192.
25. Cerone M, Ward R, Londoño-Vallejo J and Autexier C. Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation. Cell Cycle 2005;4:585-589.
26. Danzy S, Su CY, Park S, Li SY, Ferraris AM and Ly H. Absence of pathogenic mutations of the human telomerase RNA gene (hTERC) in patients with chronic myeloproliferative disorders. Leukemia 2006;20:893-894.
27. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, Read EJ, Lansdorp PM and Young NS. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003; 362:1628-1630.
28. Fu D and Collins K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. Mol Cell 2003; 11: 1361-1372.
29. Ly H, Calado RT, Allard P, Baerlocher GM, Lansdorp PM, Young NS and Parslow TG. Functional characterization of telomerase RNA variants found in patients with hematological disorders. Blood 2005;105: 2332-2339.
30. Ly H, Schertzer M, Jastaniah W, Davis J, Yong SL, Ouyang Q, Blackburn EH, Parslow TG and Lansdorp PM. Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita. Blood 2005;106:1246-1252.
31. Marrone A, Sokhal P, Walne A, Beswick R, Kirwan M, Killick S, Williams M, Marsh J, Vulliamy T and Dokal I. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007;92:1013-1020.
32. Marrone A, Stevens D, Vulliamy T, Dokal I and Mason PJ. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood 2004; 104:3936-3942.
33. Ortmann CA, Niemeyer CM, Wawer A, Ebell W, Baumann I and Kratz CP. TERC mutations in children with refractory cytopenia. Haematologica 2006;91:707-708.
34. Theimer CA, Finger LD and Feigon J. YNMG tetraloop formation by a dyskeratosis congenita mutation in human telomerase RNA. RNA 2003;9:1446-1455.
35. Theimer CA, Finger LD, Trantirek L and Feigon J. Mutations linked to dyskeratosis congenita cause changes in the structural equilibrium in telomerase RNA. Proc Natl Acad Sci USA 2003;100:449-454.
36. Vulliamy T, Marrone A, Dokal I and Mason PJ. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002; 359: 2168-2170.
37. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ and Dokal I. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432-435.
38. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ and Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004;36:447-449.
39. Wilson DB, Ivanovich J, Whelan A, Goodfellow PJ and Bessler M. Human telomerase RNA mutations and bone marrow failure. Lancet 2003;361:1993-1994.
40. Yamaguchi H, Baerlocher GM, Lansdorp PM, Chanock SJ, Nunez O, Sloand E and Young NS. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003;102: 916-918.
41. Alder JK, Chen JJL, Lancaster L, Danoff S, Su S-c, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA, Lansdorp PM, Loyd JE and Armanios MY. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008;105:13051-13056.
42. Field JJ, Mason PJ, An P, Kasai Y, McLellan M, Jaeger S, Barnes YJ, King AA, Bessler M and Wilson DB. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. Pediatr Hematol Oncol 2006;28:450-453.
43. Takeuchi J, Ly H, Yamaguchi H, Carroll KA, Kosaka F, Sawaguchi K, Mitamura Y, Watanabe A, Gomi S, Inokuchi K and Dan K. Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells Mol Dis 2008;40: 185-191.
44. Ding Y, Zhu T, Jiang W, Yang Y, Bu D, Tu P, Zhu X and Wang B. Identification of a novel mutation and a de novo mutation in DKC1 in two Chinese pedigrees with Dyskeratosis congenita. J Invest Dermatol 2004;123:470-473.
45. Heiss NS, Megarbane A, Klauck SM, Kreuz FR, Makhoul E, Majewski F and Poustka A. One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). Genet Couns 2001;12: 129-136.
46. Hiramatsu H, Fujii T, Kitoh T, Sawada M, Osaka M, Koami K, Irino T, Miyajima T, Ito M, Sugiyama T and Okuno T. A novel missense mutation in the DKC1 gene in a Japanese family with X-linked dyskeratosis congenita. Pediatr Hematol Oncol 2002;19:413-419.
47. Kanegane H, Kasahara Y, Okamura J, Hongo T, Tanaka R, Nomura K, Kojima S and Miyawaki T. Identification of DKC1 gene mutations in Japanese patients with X-linked dyskeratosis congenita. Br J Haematol 2005; 129:432-434.
48. Knight SW, Heiss NS, Vulliamy TJ, Aalfs CM, McMahon C, Richmond P, Jones A, Hennekam RC, Poustka A, Mason PJ and Dokal I. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol 1999;107:335-339.
49. Knight SW, Heiss NS, Vulliamy TJ, Greschner S, Stavrides G, Pai GS, Lestringant G, Varma N, Mason PJ, Dokal I and Poustka A. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999;65:50-58.
50. Knight SW, Vulliamy TJ, Morgan B, Devriendt K, Mason PJ and Dokal I. Identification of novel DKC1 mutations in patients with dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet 2001;108:299-303.
51. Kraemer DM and Goebeler M. Missense mutation in a patient with X-linked dyskeratosis congenita. Haematologica 2003;88:ECR11-.
52. Lin JH, Lee JY, Tsao CJ and Chao SC. DKC1 gene mutation in a Taiwanese kindred with X-linked dyskeratosis congenita. Kaohsiung J Med Sci 2002;18:573-577.
53. Salowsky R, Heiss N, Benner A, Wittig R and Poustka A. Basal transcription activity of the dyskeratosis congenita gene is mediated by Sp1 and Sp3 and a patient mutation in a Sp1 binding site is associated with decreased promoter activity. Gene 2002;293:9-19.
54. Sznajer Y, Baumann C, David A, Journel H, Lacombe D, Perel Y, Blouin P, Segura JF, Cezard JP, Peuchmaur M, Vulliamy T, Dokal I and Verloes A. Further delineation of the congenital form of X-linked dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome). Eur J Pediatr 2003;162:863-867.
55. Vulliamy TJ, Knight SW, Heiss NS, Smith OP, Poustka A, Dokal I and Mason PJ. Dyskeratosis congenita caused by a 3′ deletion: germline and somatic mosaicism in a female carrier. Blood 1999;94:1254-1260.
56. Yaghmai R, Kimyai-Asadi A, Rostamiani K, Heiss NS, Poustka A, Eyaid W, Bodurtha J, Nousari HC, Hamosh A and Metzenberg A. Overlap of dyskeratosis congenita with the Hoyeraal-Hreidarsson syndrome. J Pediatr 2000;136:390-393.
57. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, Poustka A and Dokal I. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998;19:32-38.
58. Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, Al-Qurashi FH, Aljurf M and Dokal I. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007;16:1619-1629.
59. Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A and Dokal I. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proceedings of the National Academy of Sciences 2008; 105: 8073-8078.
60. Savage SA, Calado RT, Xin ZT, Ly H, Young NS and Chanock SJ. Genetic variation in telomeric repeat binding factors 1 and 2 in aplastic anemia. Exp Hematol 2006;34:664-671.
61. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM and Alter BP. TINF2, a Component of the Shelterin Telomere Protection Complex, Is Mutated in Dyskeratosis Congenita. Am J Hum Genet 2008;82:501-509.
62. Walne AJ, Vulliamy T, Beswick R, Kirwan M and Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008;112:3594-3600.
63. Du H-Y, Mason PJ, Bessler M and Wilson DB. TINF2 mutations in children with severe aplastic anemia. Pediatr Blood Cancer 2008;52:687.
64. Tsangaris E, Adams SL, Yoon G, Chitayat D, Lansdorp P, Dokal I and Dror Y. Ataxia and pancytopenia caused by a mutation in TINF2. Hum Genet 2008;124:507-513.
65. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110: 768-779.
66. Alter BP, Giri N, Savage SA and Rosenberg PS. Cancer in dyskeratosis congenita. Blood 2009 [Epub ahead of print].
67. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, Peters JA, Giri N and Lansdorp PM. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007;110:1439-1447.
68. Du H-Y, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, Wilson DB, Mason PJ and Bessler M. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009; 113:309-316.
69. Marrone A, Walne A and Dokal I. Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr Opin Genet Dev 2005;15: 249-257.
70. He J, Navarrete S, Jasinski M, Vulliamy T, Dokal I, Bessler M and Mason PJ. Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice. Oncogene 2002; 21: 7740-7744.
71. Hreidarsson S, Kristjansson K, Johannesson G and Johannsson JH. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr Scand 1988; 77:773-775.
72. Berthet F, Tuchschmid P, Boltshauser E and Seger RA. The Hoyeraal-Hreidarsson syndrome: don't forget the associated immunodeficiency. Eur J Pediatr 1995;154: 998.
73. Errington TM, Fu D, Wong JMY and Collins K. Disease-Associated Human Telomerase RNA Variants Show Loss of Function for Telomere Synthesis without Dominant-Negative Interference. Mol Cell Biol 2008;28:6510-6520.
74. Shastry BS. Heritable trinuclotide repeats and neurological disorders. Experientia 1994;50: 1099-1105.
75. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA and Greider CW. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
76. Herrera E, Samper E, Martin-Caballero J, Flores JM, Lee HW and Blasco MA. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 1999;18:2950-2960.
77. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW and DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-574.
78. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C and DePinho RA. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-712.
79. Young NS. Acquired aplastic anemia. Ann Intern Med 2002;136:534-546.
80. Calado RT, Graf SA, Wilkerson KL, Kajigaya S, Ancliff PJ, Dror Y, Chanock SJ, Lansdorp PM and Young NS. Mutations in the SBDS gene in acquired aplastic anemia. Blood 2007;110: 1141-1146.
81. Estey E and Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
82. Young NS, Calado RT and Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509-2519.
83. Bessler M, Schaefer A and Keller P. Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology. Transfus Med Rev 2001;15:255-267.
84. Kinoshita T and Inoue N. Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria. Int J Hematol 2002; 75:117-122.
85. Keith WN, Vulliamy T, Zhao J, Ar C, Erzik C, Bilsland A, Ulku B, Marrone A, Mason PJ, Bessler M, Serakinci N and Dokal I. A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. BMC Blood Disord 2004;4:3.
86. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214-4222.
87. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN and Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
88. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
89. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ and Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
90. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148.
91. Gross TJ and Hunninghake GW. Idiopathic Pulmonary Fibrosis. N Engl J Med 2001;345: 517-525.
92. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N and Choi AMK. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006;203: 2895-2906.
93. Cerruti Mainardi P. Cri du Chat syndrome. Orphanet J Rare Dis 2006;1:33.
94. Zhang A, Zheng C, Hou M, Lindvall C, Li KJ, Erlandsson F, Björkholm M, Gruber A, Blennow E and Xu D. Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome. Am J Hum Genet 2003;72:940-948.
95. Gu B-W, Bessler M and Mason PJ. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci USA 2008;105: 10173-10178.
96. Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH, Cordon-Cardo C and Pandolfi PP. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003;299:259-262.
97. Yoon A, Peng G, Brandenburg Y, Zollo O, Xu W, Rego E and Ruggero D. Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita. Science 2006;312: 902-906.
98. Mochizuki Y, He J, Kulkarni S, Bessler M and Mason PJ. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 2004;101:10756-10761.
99. Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, Wakeham A, Itie A, Siderovski DP, Lansdorp PM, Robinson MO and Harrington L. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 2000; 10:1459-1462.
100. Yuan X, Ishibashi S, Hatakeyama S, Saito M, Nakayama J, Nikaido R, Haruyama T, Watanabe Y, Iwata H, Iida M, Sugimura H, Yamada N and Ishikawa F. Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes Cells 1999;4:563-572.
101. Erdmann N, Liu Y and Harrington L. Distinct dosage requirements for the maintenance of long and short telomeres in mTert heterozygous mice. Proc Natl Acad Sci USA 2004;101:6080-6085.
102. Niida H, Matsumoto T, Satoh H, Shiwa M, Tokutake Y, Furuichi Y and Shinkai Y. Severe growth defect in mouse cells lacking the telomerase RNA component. Nat Genet 1998;19:203-206.
103. Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, Huso D and Greider CW. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005;123:1121-1131.
104. Rajaraman S, Choi J, Cheung P, Beaudry V, Moore H and Artandi SE. Telomere uncapping in progenitor cells with critical telomere shortening is coupled to S-phase progression in vivo. Proc Natl Acad Sci USA 2007;104: 17747-17752.
105. Bollmann FM. The many faces of telomerase: emerging extratelomeric effects. BioEssays 2008; 30: 728-732.
106. Chung HK, Cheong C, Song J and Lee H-W. Extratelomeric Functions of Telomerase. Curr Mol Med 2005;5:233-241.
107. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, Wang E, Artandi MK, Oro AE and Artandi SE. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 2005;436:1048-1052.
108. Chiang YJ, Kim S-H, Tessarollo L, Campisi J and Hodes RJ. Telomere-Associated Protein TIN2 Is Essential for Early Embryonic Development through a Telomerase-Independent Pathway. Mol Cell Biol 2004; 24:6631-6634.
109. Karlseder J, Kachatrian L, Takai H, Mercer K, Hingorani S, Jacks T and de Lange T. Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol 2003;23:6533-6541.
110. Celli GB and de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005;7:712-718.
111. He H, Wang Y, Guo X, Ramchandani S, Ma J, Shen M-F, Garcia DA, Deng Y, Multani AS, You MJ and Chang S. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol Cell Biol 2009; 29:229-240.
112. Hockemeyer D, Daniels J-P, Takai H and de Lange T. Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 2006; 126:63-77.
113. Hockemeyer D, Palm W, Wang RC, Couto SS and de Lange T. Engineered telomere degradation models dyskeratosis congenita. Genes Dev 2008;22:1773-1785.
114. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, Bachilo O, Pathak S, Tahara H, Bailey SM, Deng Y, Behringer RR and Chang S. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 2006;126:49-62.
115. Zinsser F. Atrophia cutis reticularis cum pigmentatione, dystrophia unguium et leukoplakia oris. Ikonogr Dermatol (Hyoto) 1906;5:219-223.
116. Greider CW and Blackburn EH. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell 1985; 43:405-413.
117. Chen J. Animal models for acquired bone marrow failure syndromes. Clin Med Res 2005;3:102-108.